| Literature DB >> 33225037 |
Jens H Højvig1, Nicolas J Pedersen1, Birgitte W Charabi2, Irene Wessel2, Lisa T Jensen1, Jan Nyberg3, Nana Mayman-Holler4, Henrik Kehlet5, Christian T Bonde1.
Abstract
INTRODUCTION: Microvascular reconstructions after head and neck cancer are among the most complicated procedures in plastic surgery. Postoperative complications are common, which often leads to prolonged hospital stay. Enhanced recovery after surgery (ERAS) is a peri- and postoperative care concept with the aim of achieving pain- and risk-free surgery. It has been previously established as superior to conventional care for a wide variety of procedures, including microsurgical procedures such as reconstructions of the breast. Several ERAS protocols for microvascular head and neck cancer reconstructions have been proposed, although most of these are based on extrapolated evidence from different surgical specialties. Results from the implementation of ERAS for these procedures are inconsistent.Entities:
Keywords: ERAS; Head and neck; enhanced recovery after surgery; free flap surgery; head and neck cancer; microvascular reconstruction
Year: 2020 PMID: 33225037 PMCID: PMC7666314 DOI: 10.1016/j.jpra.2020.09.008
Source DB: PubMed Journal: JPRAS Open ISSN: 2352-5878
Demographic and disease-related data of OS and LP microvascular reconstructions.
| OS group (58) | LP group (31) | Total (89) | |
|---|---|---|---|
| Sex Male (%) Female (%) | |||
| Age, years (range) | 62.3 (31-84) | 64.4 (44-81) | 62.9 (31-84) |
| BMI (range) | 24.5 (14-34) | 22.6 (13-34) | 24.9 (13-34) |
| Tobacco use (%) Active smokers Former smokers Nonsmokers | |||
| Comorbidities (%) Diabetes Hypertension Pulmonary disease Ischemic heart disease | |||
| Primary cancer/procedure (%) | 33 (57) | 4 (13) | 37 (42) |
| Recurrent disease (%) Previous surgery Previous radiation Both |
Data are presented as average (range) or numerical (% of column).
Procedure-related data of OS and LP microvascular reconstructions.
| OS group (58) | LP group (31) | Total (89) | |
|---|---|---|---|
| Cancer location (%) Oral cavity, lower Oral cavity, upper Sinus & nasal cavity Pharyngeal/Laryngeal | |||
| Tumor type (%) Squamous cell carcinoma Osteosarcoma Adenoid cystic carcinoma Other | |||
| Operating time, avg. (min) | 564 (346-838) | 546 (376-797) | 558(346-838) |
| Blood loss, avg. (ml) | 1330 (170-2700) | 662 (<100-1900) | 1097 (<100-2700) |
| Blood transfusion (%) SAG-M FFP | |||
| Flap type (%) Free Fibula Flap Latissimus dorsi Anterolateral thigh Radial forearm Free fibula + LD/ALT | |||
| Foreign body (%) Titanium plate (with FFF) Titanium plate (wrap-around) Titanium mesh |
Data are presented as average (SD) or numerical (% of column).
Includes area around the mandible, floor of mouth, tongue root, and gingiva.
Upper part of the oral cavity includes soft and hard palate, maxilla, and fauces.
Figure 1Graphical overview of factors responsible for keeping patients in the hospital for the oral cavity & sinus group. The graphs show the percentage of patients that remain to solve the current factor at a given time.
Figure 2Graphical overview of factors responsible for keeping patients in the hospital for the laryngopharyngeal group. The graphs show the percentage of patients that remain to solve the current factor at a given time.
Data regarding primary hospitalization after OS and LP microvascular reconstructions.
| OS group (58) | LP group (31) | Total (89) | |
|---|---|---|---|
| Length of stay | 20.3 (8-70) | 20.3 (11-135) | 20.3 (8-135) |
| ICU stay, avg. (h) | 33.3 (10-212) | 24.2 (17-89) | 30.0 (10-212) |
| Nasogastric tube Duration After discharge Conversion to PEG | 58 (100) | 31 (100) | 89 (100) |
| Tracheostomy Time to closure, days Provox gauge, NO | 52 (90%) | 2 (6) | |
| Time to ambulation, days | 6.4 (1-19) | 4.3 (2-8) | 5.7 (1-19) |
Data are presented as average (SD) or numerical (% of column).
Data regarding complications after OS and LP microvascular reconstructions.
| OS group (58) | LP group (31) | Total (89) | |
|---|---|---|---|
| Infection (%) Donor site Recipient site UTI Pulmonary Unknown | 19 (33) | 14 (45) | 33 (37) |
| Re-operations 30 days, NO patients Hematoma Flap loss Tracheostomy problem Flap revision Donor-site complications Abscess | 13 (22) | 4 (13) | 17 (19) |
| Re-admissions Infection Nutritional problem Wound revision Tracheostomy problem | 6 (10) | 9 (29) | 15 (17) |
| Postoperative mortality | 1 (2) | 0 | 1 (1) |
Data are presented as average (SD) or numerical (% of column).
Displays the number of procedures performed rather than the number of patients.
List of our functional discharge criteria.
| List of functional discharge criteria | |
|---|---|
| Full ambulation | walking unrestricted |
| Sufficient nutrition | Intake of calculated daily nutritional calorie requirement |
| Sufficient pain relief | No need for analgesia in excess of the per oral opioid-sparing regimen |
| No suspected infection | Normothermia & normal biochemical infection parameters |
| Closure of tracheostomy | Closure or thorough education in self-management of tracheostoma |
| Bowel function | Stool and flatulence passing |